CN116963736A - 马赛替尼用于治疗阿尔茨海默病 - Google Patents

马赛替尼用于治疗阿尔茨海默病 Download PDF

Info

Publication number
CN116963736A
CN116963736A CN202180093808.7A CN202180093808A CN116963736A CN 116963736 A CN116963736 A CN 116963736A CN 202180093808 A CN202180093808 A CN 202180093808A CN 116963736 A CN116963736 A CN 116963736A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
treatment
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180093808.7A
Other languages
English (en)
Chinese (zh)
Inventor
阿兰·穆塞
C·曼斯菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AB Science SA
Original Assignee
AB Science SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AB Science SA filed Critical AB Science SA
Publication of CN116963736A publication Critical patent/CN116963736A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN202180093808.7A 2020-12-16 2021-12-16 马赛替尼用于治疗阿尔茨海默病 Pending CN116963736A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306589 2020-12-16
EP20306589.1 2020-12-16
PCT/EP2021/086308 WO2022129410A1 (en) 2020-12-16 2021-12-16 Masitinib for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
CN116963736A true CN116963736A (zh) 2023-10-27

Family

ID=74141317

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180093808.7A Pending CN116963736A (zh) 2020-12-16 2021-12-16 马赛替尼用于治疗阿尔茨海默病

Country Status (10)

Country Link
US (1) US20240058328A1 (cg-RX-API-DMAC7.html)
EP (1) EP4262801A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023554354A (cg-RX-API-DMAC7.html)
KR (1) KR20230125804A (cg-RX-API-DMAC7.html)
CN (1) CN116963736A (cg-RX-API-DMAC7.html)
AU (1) AU2021399925A1 (cg-RX-API-DMAC7.html)
CA (1) CA3201259A1 (cg-RX-API-DMAC7.html)
IL (1) IL303521A (cg-RX-API-DMAC7.html)
MX (1) MX2023007029A (cg-RX-API-DMAC7.html)
WO (1) WO2022129410A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025113494A1 (zh) * 2023-11-27 2025-06-05 浙江径科医药有限公司 多环类化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
HRP20110709T1 (hr) 2007-02-13 2011-11-30 Ab Science Postupak sinteze spojeva 2-aminotioazola kao inhibitora kinaza
AR080380A1 (es) * 2010-03-09 2012-04-04 Ab Science Tratamiento de la demencia tipo alzheimer con masitinib

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PIETTE等: "Masitinib as an adjunct therapy for mild-to-moderate Alzheimer’s disease: a randomised, placebo-controlled phase 2 trial", 《ALZHEIMER’S RESEARCH & THERAPY》, vol. 3, no. 2, 19 April 2011 (2011-04-19), pages 1 - 11, XP021102296, DOI: 10.1186/alzrt75 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025113494A1 (zh) * 2023-11-27 2025-06-05 浙江径科医药有限公司 多环类化合物及其应用

Also Published As

Publication number Publication date
WO2022129410A1 (en) 2022-06-23
EP4262801A1 (en) 2023-10-25
KR20230125804A (ko) 2023-08-29
AU2021399925A1 (en) 2023-06-29
JP2023554354A (ja) 2023-12-27
US20240058328A1 (en) 2024-02-22
IL303521A (en) 2023-08-01
MX2023007029A (es) 2023-07-18
CA3201259A1 (en) 2022-06-23
AU2021399925A9 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
CN108883108B (zh) 马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途
WO2009017455A1 (en) A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
US20180311236A1 (en) Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease
JP7731868B2 (ja) TDP-43、α-シヌクレイン、ハンチンチンタンパク質及びタウタンパク質のオリゴマー形成に関連する疾患を治療するための小分子薬物、並びに関連する方法
US20170119760A1 (en) Use of masitinib for the treatment of progressive supranuclear palsy
JP7788154B2 (ja) 多発性硬化症患者の亜集団の処置のためのマシチニブ
US8513280B2 (en) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
JP2025176192A (ja) 好酸球性喘息の処置のためのmasitinibの使用
JP2023554354A (ja) アルツハイマー病の処置のためのマシチニブ
CZ27299A3 (cs) Způsob léčení bipolární afektivní poruchy
WO2008069726A1 (en) Treatment of resistant schizophrenia and other cns disorders by the use of thioxanthenes
CN117337177A (zh) 马赛替尼用于治疗去势抵抗性前列腺癌
EP0821958A2 (en) Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
HK1261581B (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
WO2022060978A1 (en) Methods of treating parkinson's disease and related disorders with pde10a inhibitors
HK1008931A (en) Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline ) for treating excessive aggression
HK1008932A (en) Use of 3-(4-hexyloxy-1,2,5-thiadiazol -3-yl)-1,2,5,6,-tetrahydro-1-methylpyridine (xanomeline) for treating bipolar disorder

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination